| Title | Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. |
| Publication Type | Journal Article |
| Year of Publication | 2009 |
| Authors | Mark T, Martin P, Leonard JP, Niesvizky R |
| Journal | Expert Opin Investig Drugs |
| Volume | 18 |
| Issue | 1 |
| Pagination | 99-104 |
| Date Published | 2009 Jan |
| ISSN | 1744-7658 |
| Keywords | Animals, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antigens, Differentiation, B-Lymphocyte, Clinical Trials as Topic, Drug Evaluation, Preclinical, Histocompatibility Antigens Class II, Humans, Immunotherapy, Lymphoma |
| Abstract | BACKGROUND: Non-Hodgkin's lymphoma and multiple myeloma are often incurable and respond to a limited set of treatment options. The selective expression of CD74, the invariant chain of the MHC class II molecule, in these malignancies provides an attractive target for antibody-based therapy. OBJECTIVE: This review evaluates the preclinical data for milatuzumab, a humanized antibody targeting CD74, as a treatment for non-Hodgkin's lymphomas and multiple myeloma. METHODS: A review of the literature was carried out using PubMed. Current Phase I protocols using milatuzumab are summarized. RESULTS/CONCLUSION: Milatuzumab is cytotoxic to lymphoma and multiple myeloma cell lines and mouse-human xenografts. The efficacy dramatically increases when milatuzumab is attached to a toxin or a radioactive agent. Phase I trials of milatuzumab are now underway in human subjects with lymphoma and multiple myeloma. |
| DOI | 10.1517/13543780802636162 |
| Alternate Journal | Expert Opin Investig Drugs |
| PubMed ID | 19053886 |